HEALTH OF WOMAN. 2019.1(137):101–104; doi 10.15574/HW.2019.137.101

Litvak O. O.
Shupyk National Medical Academy of Postgraduate Education, Kiev
SSE «Scientific and practical center of preventive and clinical medicine» SAA, Kiev

The objective: to conduct morphological research of myomatous tissue and an endometriya at patients with uterus leiomyoma after treatment by preparation ulipristale acetate.

Materials and methods. Histological and immunohistochemical research of the leiomyomas removed by myomectomy, and an endometriya at 15 patients after trimensual course of treatment by preparation ulipristale acetate – 5 mg at days on (patients with uterus leiomyoma without endocrine pathology) is conducted. In control group investigated 15 leiomyomas at o women without preoperative hormonal therapy.

Results. At patients who accepted ulipristale acetate in the cells of leiomyoma reliable depression of an expression of receptors of Progesteronum, markers of inhibitor of apoptosis of Вcl-2 and proliferative activity of Кi-67 became perceptible. In the leiomyoma cells under influence ulipristale acetate there is decrease of quantity of receptors of Progesteronum, its action owing to what there is induction of apoptosis and depression of processes of proliferation at the expense of what there is leiomyoma involution decreases. Endometrium at treatment ulipristale acetate gets characteristic changes which need to be differentiated about estrogen the induced changes or hyperplasia.

Conclusion. The received results needs to be considered when developing tactics of maintaining women with uterus leiomyoma.

Key words: uterus leiomyoma, medicamental correction, morphology.

REFERENCES

1. Sidorova IS. (2014). Morfogenez i angiogenez prostyih i proliferiruyuschih miom matki. Rossiyskiy vestnik akushera-ginekologa 4;1:8-11.

2. Okoro Bonaventure. (2016). Sovremennyie podhodyi k vyiboru lechebnoy taktiki vedeniya bolnyih s miomoy matki. MIzhnarodniy medichniy zhurnal: 22;2:43-46.

3. Tatarchuk TF. (2016). MIoma matki: lIkuvannya z metoyu dovgostrokovogo kontrolyu. ZhInochiy lIkar 1:3-7.

4. Tatarchuk TF. (2016). Organosohranyayuschee lechenie simptomnoy leyomiomyi matki u patsientok reproduktivnogo vozrasta. Reproduktivna endokrinologіya 2(28)94-99.

5. Tatarchuk TF. (2014). Novaya era v lechenii miomyi matki u zhenschin razlichnyih vozrastnyih grup. Reproduktivna endokrinologіya 6(20):9-19.

6. Burlev VA. (2017). Lokalnyiy i sistemnyiy angiogenez u bolnyih s miomoy matki. Problemyi reproduktsii 13;1:26-33.

7. Davyidov AI. (2016). Vozmozhnosti 3D transvaginalnoy ehografii v diagnostike dobrokachestvennyih zabolevaniy matki i pridatkov. Voprosy ginekologii, akusherstva i perinatologii 1:47-52.

8. Kamenetskiy B. (2011). Dopplerometriya krovotoka v sosudah matki kak prognosticheskiy faktor pri lechenii besplodiya metodami vspomogatelnoy reproduktsii. Problemy reproduktsii 4:4-17.

9. Dubuisson JB. (2011). Laparoscopic myomectomy fertility results. Ann. N Y. Acad. Sci. 943: 269-275. https://doi.org/10.1111/j.1749-6632.2001.tb03807.x; PMid:11594546

10. Zadorozhna TD. (2013). Morfolohichni metody doslidzhennia miomy matky. Morfologiia 2: 43-49.